Cost-effectiveness of highly active antiretroviral therapy in South Africa.
about
Is antiretroviral therapy cost-effective in South Africa?A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomesPublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedElimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison studyThe Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit AnalysisThe cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008Rising population cost for treating people living with HIV in the UK, 1997-2013Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.Healthcare utilization of patients accessing an African national treatment program.Late entry to HIV care limits the impact of anti-retroviral therapy in The NetherlandsUtility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited settingEnsuring the involvement of children in the evaluation of new tuberculosis treatment regimensEarly severe morbidity and resource utilization in South African adults on antiretroviral therapy.Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisLong-term costs and health impact of continued global fund support for antiretroviral therapyThe cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention.Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa.Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South AfricaTreatment as prevention: preparing the wayThe cost of providing comprehensive HIV treatment in PEPFAR-supported programs.Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa.The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South AfricaProjected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study.The determinants of HIV treatment costs in resource limited settings.Cost-effectiveness of antiretroviral therapy for preventionThe cost of antiretroviral therapy in Haiti.The cost-effectiveness of antiretroviral therapy for treating HIV disease in the CaribbeanS4HARA: System for HIV/AIDS resource allocationEstimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis.Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia.The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care.
P2860
Q25255972-DAD6CDB1-5793-4670-B6B4-43BBD11FB7ADQ26796419-6067E77D-7CFF-4A85-8936-E62EDFCFFE6AQ28473120-EE14CD96-72DA-4931-B788-66CD74CB9395Q28534568-DB74224C-A557-485A-8EED-856B457F1CDAQ28608172-77EB8A35-D918-4709-AC76-D67671AA51EBQ28741478-1BBACDB7-50B2-4690-A3F3-9E45C190CF27Q28743848-56B51A2D-E8CA-4186-B650-EBBF4A3C80B3Q28744286-3DFB5A0B-720A-41F5-9C92-BEAC31287A41Q31026449-1E74D549-83BC-4A38-B7C8-F11BE25FE416Q33287043-8B9C2CF2-FB54-4CEA-936D-784FD5594D62Q33327368-D593C577-0534-4708-A600-FEEE54C37CD4Q33349204-E3C3D356-89D3-459D-B6B7-EC67F38BFB13Q33361748-84AA548C-7212-4BC6-B8CA-525233415AD3Q33518021-09E0F0C1-04AA-4729-9024-D8D73894484BQ33950833-2279EACD-D5E3-4B01-801F-2ABFD13AA1E5Q33952153-49AFC19C-EAA5-477F-8888-FE63E8897485Q34029513-4E8AF021-5FDF-4F8B-8F57-B838BDBE0B4BQ34341297-38CA881E-592A-4799-970F-347C3EA4F44CQ34353431-FF1AC11E-6ED0-46D1-8B07-926420AAF6CEQ34464437-35F40662-F25F-4413-99BB-C8CAC5D9052CQ34532698-7ED16A5B-09BF-4009-B692-9332068E917FQ34583843-C3D5FDCF-E9A1-44D8-85CD-B0234486C4F6Q34735093-0A1E5D14-9BA0-4F37-AD3A-22B28413D7C2Q34768650-219CB004-89A0-4734-825B-206A6FC61B55Q35120904-2BFDA5C0-9BE5-4042-9391-3A3D6B4CD711Q35357663-0CE01A5D-5175-4C15-B5B3-4BF34545340BQ35576296-5856CD85-54A7-4694-AF5E-FFD5E04E36A2Q35854983-8F7549DF-20C6-4C32-83F5-19473E51A1EBQ35925982-D9C4C1A1-1322-45D5-AA4B-0975717E0916Q35990326-64E0449D-3943-47B2-AE77-36BBF01B4F44Q36095394-A796F570-9C9B-4641-B7D6-AA1F89795DA8Q36381028-557DFA05-ECAC-4024-8DAE-731E991A2455Q36486226-B0B19F2E-7849-4F6C-8615-55D1E355E8C4Q36512486-89E8EC5D-481E-431A-AB24-1DC0EAC753B0Q36628346-9E2C8BEA-A02D-43C4-A195-C4781A261356Q36661454-F588C516-12A0-4C67-B2A5-80615F49C2A3Q37063081-0C14A805-C5E5-4218-BBD0-F104FC2A1C40Q37151512-A5E62B23-801F-4BD3-A55E-79E4A5DEF7D1Q37166426-2D0243CD-F61F-4FEB-A6EE-8CFCC5A8BB4BQ37207523-B187322F-C7D7-47FF-B5A0-782F80AD82DE
P2860
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cost-effectiveness of highly active antiretroviral therapy in South Africa
@nl
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@ast
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@en
type
label
Cost-effectiveness of highly active antiretroviral therapy in South Africa
@nl
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@ast
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@en
prefLabel
Cost-effectiveness of highly active antiretroviral therapy in South Africa
@nl
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@ast
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@en
P2093
P2860
P50
P3181
P1433
P1476
Cost-effectiveness of highly active antiretroviral therapy in South Africa.
@en
P2093
Eduard J Beck
John R Penrod
Sundhiya Mandalia
P2860
P3181
P356
10.1371/JOURNAL.PMED.0030004
P407
P577
2005-12-06T00:00:00Z